FDA Advisory Panel Unanimously Favors New Stool DNA Colorectal Screening Test 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Panel’s Comments

“I typically refrain from commentary, but I will say this: I think this is a phenomenal study, in particular, for one reason,” said FDA panel member Ronald Przygodzki, acting director of Biomedical Laboratory Research and Development at the Department of Veterans Affairs Office of Research & Development.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login